Table 1.
Association between the possibility of DCB/NDB and tumor‐specific gene mutations
| Gene | NDB (n = 24) | DCB (n = 20) | P‐value |
|---|---|---|---|
| Pan‐ErbB | |||
| 1 | 12 | 4 | 0.039 |
| 0 | 12 | 16 | |
| KRAS | |||
| 1 | 1 | 13 | <0.001 |
| 0 | 23 | 7 | |
| BRCA | |||
| 1 | 7 | 2 | 0.117 |
| 0 | 17 | 18 | |
| EML4‐ALK | |||
| 1 | 0 | 3 | 0.049 |
| 0 | 24 | 17 | |
| PIk3CA | |||
| 1 | 2 | 2 | 1.000 |
| 0 | 22 | 18 | |
| MET | |||
| 1 | 3 | 2 | 1.000 |
| 0 | 21 | 18 | |
| TP53 | |||
| 1 | 6 | 11 | 0.042 |
| 0 | 18 | 9 | |
| FGFR | |||
| 1 | 2 | 2 | 1.000 |
| 0 | 22 | 18 | |
| BRAF | |||
| 1 | 2 | 2 | 1.000 |
| 0 | 22 | 18 | |
| CDK4/6 | |||
| 1 | 5 | 1 | 0.279 |
| 0 | 19 | 19 | |
| POLE | |||
| 1 | 3 | 2 | 1.000 |
| 0 | 21 | 18 | |
| POLD1 | |||
| 1 | 1 | 1 | 1.000 |
| 0 | 23 | 19 | |
| BLM | |||
| 1 | 2 | 0 | 0.493 |
| 0 | 22 | 20 | |
| JAK1/2/3 | |||
| 1 | 0 | 4 | 0.030 |
| 0 | 24 | 16 | |
| PTEN | |||
| 1 | 1 | 6 | 0.035 |
| 0 | 23 | 14 | |
| TP53 + PTEN | |||
| 1 | 0 | 4 | 0.036 |
| 0 | 24 | 16 | |
| KRAS + TP53 | |||
| 1 | 0 | 6 | 0.005 |
| 0 | 24 | 14 |
Bold font means P value <0.05, suggesting statistical significance.